While I agree that BP clearly explained how Leronlimab will impact the virus in its various stages. we’re talking about a subjective data point the scoring system 1-12 on PE for people who largely get better on their own.. You’re holding out for statistical significance for the PE?? ...i actually don’t understand your point.. they been crunching data for a month now they didn’t get to that easy one first?

Sure hope nobody took my post as being anything other than cautiously optimistic.. nothing i wrote suggest making investing decisions based off reading between the lines or hypothetical results. Investors who follow the CEO should understand now that the PH2 was designed to look at these exploratory endpoints. And that the team is confident in the drug efficacy. An EUA however and whenever it comes will sell out stock out this year and make a couple billion on the way (that’s from NP stating this for a long time now). Maybe more if we get lucky

So if you’re reading: buy!